Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
A report released today by The National Alliance for Caregiving (NAC), with support from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and Arcadia University, uncovers the immense, ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
What happened: Columbia Borough school board will vote Feb. 20 on whether to spend $1.48 million over the next five years to ...
Congratulations to this year’s Distinguished Professors, three highly accomplished faculty members who have devoted decades ...
Life-changing treatment for hand tremors in Parkinson’s and dystonia patients: Doctor reveals all you need to know about how ...
The prostate is a secondary sexual organ that sits at the ... other causes of an enlarged prostate by a healthcare provider. Parkinson’s disease refers to a movement disorder that cause ...
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...
Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback